Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Identifier
M03-596
CT.gov Identifier
NCT00645892
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
  • adalimumab
  • placebo for adalimumab
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subject participated and relapsed in prior PS study
    Exclusion Criteria:
    - Subject has other active skin diseases - Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other systemic PS therapies) - Poorly controlled medical conditions - History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease. - History of cancer or lymphoproliferative disease - History of active TB or listeriosis, or persistent chronic or active infections - Known to have immune deficiency or is immunocompromised - Clinically significant abnormal laboratory test results - Erythrodermic psoriasis or generalized pustular psoriasis

    Protocol Summary

    Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe

    Chronic Plaque Psoriasis

    Study Locations

    No locations found.